(Q37081127)

English

A randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer

scientific article published on January 2009

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

A randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer (English)

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

0 references

author name string

R L Jones

1

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

G Walsh

2

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

S Ashley

3

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

S Chua

4

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

R Agarwal

5

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

M O'Brien

6

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

S Johnston

7

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

I E Smith

8

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

language of work or name

0 references

publication date

1 January 2009

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

100

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

2

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

305-310

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634727

29 September 2017

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634727

29 September 2017

Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634727

29 September 2017

Reporting results of cancer treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634727

29 September 2017

Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634727

3 September 2018

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6604862

21 January 2018

2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel

1 reference

https://pubmed.ncbi.nlm.nih.gov/19165198

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results

1 reference

https://pubmed.ncbi.nlm.nih.gov/19165198

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome

1 reference

https://pubmed.ncbi.nlm.nih.gov/19165198

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Benefit of taxanes as adjuvant chemotherapy for early breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19165198

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/SJ.BJC.6604862

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37081127&oldid=2199845547"